Compare AMETEK, Inc. (AME) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Novo Nordisk A/S — how do they compare? AMETEK, Inc. trades at $258.64 (market cap $58.76B), while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.5× AMETEK, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| AME | NVO | |
|---|---|---|
Market Cap | $58.76B | $207.85B |
Sector | Industrials | Health |
52-Week High | $256.30 | $63.98 |
52-Week Low | $179.28 | $35.29 |
Enterprise Value | $60.30B | $222.55B |
Dividend Yield | 0.53% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME's stock trades at $257.9, up 1.99% today, reflecting strong momentum after recent earnings beats. The company reported record Q2 2026 results with EPS of $2.09, exceeding estimates, and raised full-year guidance. Valuation metrics like a P/E of 37.47 and P/S of 7.51 are elevated, but supported by robust profitability, including a 20.04% net income margin and 14.56% ROE. Technical indicators show a bullish trend, with the current price near resistance at $258.
The outlook remains positive, driven by consistent earnings growth and strong demand across business segments. Key risks include high valuation multiples and potential economic headwinds. With a consensus price target of $281.86 and no sell ratings from analysts, the stock offers upside potential, but investors should monitor execution against guidance and market volatility.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
